Overall, these results indicate an association between oncogenic KRAS activation and PD-L1/PD-1 expression and their immunosuppressive roles, which support therapeutic strategies to target KRAS-mutant cancers through abrogation of the microenvironment in pancreatic and lung cancer. This evidence concerns the gene KRAS and lung carcinoma.